Lawrence S. Blaszkowsky

Harvard University

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index55

i10-index140

Publications365

Citations16,500

Grants

No NSF/NIH grants on record.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0023

PageRank within Oncology co-authorship network

Explore collaboration map

Admission Signals

New paper: A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). (Journal of Clinical Oncology)2026-05-27
New preprint: Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab2024-10-08

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-9437-2977

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 11 of 11

A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Journal of Clinical Oncology · 2026-05-27
Tolerability and outcomes after neoadjuvant and definitive radiation of elderly patients with localized pancreatic cancer.
Journal of Clinical Oncology · 2026-01-10
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Clinical Cancer Research · 2025-12-09
Phase IB/II Study of Trifluridine/Tipiracil Hydrochloride (FTD/TPI) Plus Radiation Therapy for the Treatment of the Liver in Patients with Hepatic Metastases from Colorectal and Pancreatic Cancer
International Journal of Radiation Oncology*Biology*Physics · 2025-09-01
Pancreatic Reirradiation: A Multi-Institutional Retrospective Analysis of Feasibility, Tolerability and Clinical Outcomes
International Journal of Radiation Oncology*Biology*Physics · 2025-09-01
To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study
European Journal of Nuclear Medicine and Molecular Imaging · 2025-05-08 · 2 citations
Genomic profiling of matched tumor samples in patients with rectal cancer undergoing total neoadjuvant therapy.
Journal of Clinical Oncology · 2025-01-27
Phase II study of neoadjuvant NALIRIFOX followed by chemoradiation with paclitaxel and carboplatin in locally advanced gastroesophageal cancer.
Journal of Clinical Oncology · 2025-01-27
Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials
International Journal of Radiation Oncology*Biology*Physics · 2025-01-11 · 1 citations
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabPreprint
medRxiv · 2024-10-08 · 2 citations
Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials
International Journal of Radiation Oncology*Biology*Physics · 2024-09-27 · 1 citations

Open author page on OpenAlex →